

# PostScript

## MATTERS ARISING

### Ultrasound guided musculoskeletal injections

We read with interest the paper by Hall and Buchbinder,<sup>1</sup> which discussed the importance of accurate needle placement guided by imaging techniques in the therapeutic response to local corticosteroid injection (LCI) for musculoskeletal (MSK) conditions.

Certainly, as the authors state,<sup>1</sup> more studies providing evidence of short and long term benefit and cost effectiveness of imaging guided LCI versus blinded injection are needed. However, we would like to make some comments on a number of important points.

Firstly, Hall and Buchbinder<sup>1</sup> include in radiological guidance different imaging techniques such as radiography, computed tomography (CT), magnetic resonance imaging, and ultrasonography (US). We would like to point out that MSK US has considerable advantages over other imaging modalities as it has no secondary effects, is quick to perform, is low cost, can be repeated, and is well accepted by patients. In addition, MSK US is routinely used by an increasing number of rheumatologists from many European countries. The accuracy, safety, and simplicity of US for guiding interventional procedures in the MSK system have been widely described.<sup>2-9</sup>

Secondly, the authors mentioned the contradictory results of two papers comparing imaging guided versus blinded LCI in the shoulder.<sup>8,10</sup> We found a better clinical response to US guided than to blinded LCI,<sup>8</sup> whereas Shanahan *et al* reported a similar response to CT guided and blinded suprascapular nerve block.<sup>10</sup> Both studies were randomised, assessor blinded, and short term. Nevertheless, both interventional procedures are essentially different. In suprascapular nerve block the aim is to place the needle next to the suprascapular nerve at the suprascapular notch so that the steroid diffuses into the nerve. The use of anatomical landmarks by an experienced operator probably is enough to achieve successful placement of the LCI. On the contrary, rotator cuff, biceps tendon, and subacromial-subdeltoid bursa are located close together. Therefore accurately siting the needle in the target as well as avoiding damaging intra-tendon injection are difficult using external landmarks. In addition, CT is radioactive, expensive, and requires a radiologist, whereas US is non-invasive, available, cheap, and can be performed by a rheumatologist at the patient's bedside while accurately diagnosing shoulder lesions.

In conclusion, we would like to emphasise that US has become a powerful extension of MSK evaluation performed by many rheumatologists for improving diagnosis and interventional procedures.

**E Naredo, F Cabero, A Cruz, J Uson, M J Palop, M Crespo**

Department of Rheumatology, Hospital Severo Ochoa, Madrid, Spain

Correspondence to: Dr E Naredo, Calle Arturo Soria 259, 4<sup>o</sup> A, 28033 Madrid, Spain; esnaredo@eresmas.com

### References

- Hall S, Buchbinder R. Do imaging methods that guide needle placement improve outcome? *Ann Rheum Dis* 2004;63:1007-8.
- Koski JM. Ultrasound-guided injections in rheumatology. *J Rheumatol* 2000;27:2131-8.
- Aina R, Cardinal E, Bureau NJ, Aubin B, Brassard P. Calcific shoulder tendinitis: treatment with modified US-guided fine-needle technique. *Radiology* 2001;221:455-62.
- Koski JM, Hermunen H. Intra-articular glucocorticoid treatment of the rheumatoid wrist. An ultrasonographic study. *Scand J Rheumatol* 2001;30:268-70.
- Qvistgaard E, Kristoffersen H, Terslev L, Danneskiold-Samsøe B, Torp-Pedersen S, Bliddal H. Guidance by ultrasound of intra-articular injections in the knee and hip joints. *Osteoarthritis Cartilage* 2001;9:512-17.
- Grassi W, Farina A, Filipucci E, Cervini C. Intralesional therapy in carpal tunnel syndrome: a sonographic-guided approach. *Clin Exp Rheumatol* 2002;20:73-6.
- Balint PV, Kane D, Hunter J, McInnes IB, Field M, Sturrock RD. Ultrasound guided versus conventional joint and soft tissue fluid aspiration in rheumatology practice: a pilot study. *J Rheumatol* 2002;29:2209-13.
- Naredo E, Cabero F, Beneyto P, Cruz A, Mondejar B, Uson J, *et al*. A randomized comparative study of short-term response to blind injection versus sonographic-guided injection of local corticosteroids in patients with painful shoulder. *J Rheumatol* 2004;31:308-14.
- Fredberg U, Bolvig L, Pfeiffer-Jensen M, Clemmensen D, Jakobsen BW, Stengaard-Pedersen K. Ultrasonography as a tool for diagnosis, guidance of local steroid injection and, together with pressure algometry, monitoring of the treatment of athletes with chronic jumper's knee and Achilles tendinitis: a randomized, double-blind, placebo-controlled study. *Scand J Rheumatol* 2004;33:94-101.
- Shanahan EM, Smith MD, Wetherall M, Lott CW, Slavotinek J, FitzGerald O, *et al*. Suprascapular nerve block in chronic shoulder pain: are the radiologists better? *Ann Rheum Dis* 2004;63:1035-40.

### Authors' reply

We thank Dr Naredo and colleagues for their interest and observations.

Musculoskeletal ultrasound remains a safe, non-invasive, and (relatively) inexpensive form of imaging. It has been taken up widely by clinicians, particularly in Europe, though there has been less enthusiasm elsewhere.

However, there remains a hypothesis in need of more formal testing implicit in this communication. Naredo *et al* propose that some targets such as the suprascapular nerve can be identified by anatomical landmarks, whereas others require precise localisation through imaging to ensure therapeutic impact. Our editorial proposes that this assumption needs to be tested. Is it really mandatory to inject precisely into the subacromial-subdeltoid bursa as opposed to the rotator cuff or the biceps tendon in a patient with shoulder pain to guarantee a reduction in pain and improvement in function over the longer term?

Until there is sufficient evidence from both participant and outcome assessor blinded

### Rapid response

If you have a burning desire to respond to a paper published in the *Annals of the Rheumatic Diseases*, why not make use of our "rapid response" option?

Log on to our website ([www.annrheumdis.com](http://www.annrheumdis.com)), find the paper that interests you, and send your response via email by clicking on the "eletters" option in the box at the top right hand corner.

Providing it isn't libellous or obscene, it will be posted within seven days. You can retrieve it by clicking on "read eletters" on our homepage.

The editor will decide as before whether also to publish it in a future paper issue.

randomised trials documenting a real difference between image guided needle placement and the anatomical landmark approach over the longer term (sufficient to justify the extra cost), the requirement for precise localisation remains speculative. We welcome the results of such trials to see whether or not "the Emperor has no clothes", the fairy tale equivalent of a null hypothesis.

**S Hall**

Department of Medicine, Monash University, Box Hill Hospital, and Cabrini Hospital, Melbourne, Australia

**R Buchbinder**

Monash Department of Clinical Epidemiology at Cabrini Hospital and Department of Epidemiology and Preventive Medicine, Monash University, Suite 41 Cabrini Medical Centre, 183 Wattletree Rd, Malvern, Victoria, Australia 3144

Correspondence to: Associate Professor R Buchbinder; [rachelle.buchbinder@med.monash.edu.au](mailto:rachelle.buchbinder@med.monash.edu.au)

### Increased prevalence of ocular glaucomatous abnormalities in systemic sclerosis

Dr Allamore and team members have conducted an inspirational study into the prevalence of ocular glaucomatous abnormalities in systemic sclerosis. However, it seems that they have overlooked a major methodological flaw about the definition of glaucomatous change pertaining to normal tension glaucoma (NTG). Unless further clarification can be offered, we cannot concur with the conclusion that glaucomatous neuropathy consistent with the vascular pathogenic hypothesis for NTG was dramatically more prevalent in patients with systemic sclerosis.<sup>1</sup>

Lee *et al* have revised the definitions of NTG of several major studies.<sup>2</sup> Emphasis on maximal intraocular pressure (IOP)  $\leq 21$  mm Hg and the importance of recognising the characteristic glaucomatous optic disc change or visual field defect have been implicated.<sup>2</sup> Almost 89% of the studies/publications required the demonstration of a characteristic visual field defect on perimetry as a prerequisite for diagnosing NTG.<sup>3</sup> In the present study, the above-mentioned key features have also been adopted as the defining criteria. Moreover, defining a case with a

visual field mean deviation  $< -2$  dB was arbitrary and differed significantly from our understanding of the neuropathological basis of visual field damage specific to NTG.

Araie and coworkers have indicated that NTG and the ordinary primary open angle glaucoma or high tension glaucoma (HTG) showed significantly different visual field damage.<sup>3</sup> Visual field defects in NTG are more localised and predominant in the lower hemifield, whereas HTG has significantly more diffuse visual field damage.<sup>4-6</sup> It has been demonstrated that mean deviation in perimetry is good measure for assessing the more diffuse visual field damage characteristic of HTG but not as good for pinpointing a localised defect such as that seen in NTG.<sup>7,8</sup> Instead, pattern standard deviation or corrected pattern standard deviation were suggested as alternative indicators in representing the focal visual field defect in NTG.<sup>7,8</sup> As a result, the authors' conclusion about the relationship between NTG and systemic sclerosis may be based on an erroneous visual field index (mean deviation), which is neither sensitive nor specific for NTG.

Moreover, it should be pointed out that Allanore *et al* have adopted another arbitrary means of defining the IOP of the subjects recruited, which again showed marked disparity from our usual practice. The authors did not explain why phasing of the IOP was not undertaken given the fact that IOP shows diurnal variation, especially prominent in glaucomatous subjects such as those with NTG.<sup>9</sup> Recording of only one IOP measurement may not be sufficient owing to the influence of this confounding factor.

Appropriate case definition lies at the heart of every epidemiological research on glaucoma and any deviation from the consensual definitions may inevitably skew or even imperil the validity of the data.<sup>9</sup> In the interest of readers, we would be most grateful if the authors can provide us with more information about the rationale for the methodology used.

#### A Y K Chan

Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong SAR

#### D T L Liu

Department of Ophthalmology and Visual Sciences, Chinese University of Hong Kong, Hong Kong SAR

Correspondence to: Dr D T L Liu, Department of Ophthalmology and Visual Sciences, 7/F, Block B, Prince of Wales Hospital, Shatin, Hong Kong SAR 12345; david\_tliu@yahoo.com

## References

- Allanore Y, Pare C, Monnet D, Brezin AP, Kahan A. Increased prevalence of ocular glaucomatous abnormalities in systemic sclerosis. *Ann Rheum Dis* 2004;**63**:1276-8.
- Lee BL, Bathija R, Weinreb RN. The definition of normal-tension glaucoma. *J Glaucoma* 1998;**7**:366-71.
- Araie M, Yamagami J, Suzuki Y. Visual field defects in normal-tension and high-tension glaucoma. *Ophthalmology* 1993;**100**:1808-14.
- Araie M. Pattern of visual field defects in normal-tension and high-tension glaucoma. *Curr Opin Ophthalmol* 1995;**6**:36-45.
- Hori J, Aihara M, Suzuki Y, Araie M. Visual field defects in normal tension glaucoma and primary open angle glaucoma. Comparison in the late

stage of disease. *Nippon Ganka Gakkai Zasshi* 1994;**98**:968-73.

- Koseki N, Araie M, Suzuki Y, Yamagami J. Visual field damage proximal to fixation in normal- and high-tension glaucoma eyes. *Jpn J Ophthalmol* 1995;**39**:274-83.
- Zeiter JH, Shin DH, Juzych MS, Jarvi TS, Spoor TC, Zwas F. Visual field defects in patients with normal-tension glaucoma and patients with high-tension glaucoma. *Am J Ophthalmol* 1992;**114**:758-63.
- Yamagami J, Araie M, Suzuki Y, Shirato S, Koseki N. A comparative study of visual field damage in low-tension and primary open-angle glaucoma. *Nippon Ganka Gakkai Zasshi* 1993;**97**:383-9.
- Foster PJ, Buhrmann R, Quigley HA, Johnson GJ. The definition and classification of glaucoma in prevalence surveys. *Br J Ophthalmol* 2002;**86**:238-42.

## Authors' reply

We thank Drs Chan and Liu for their comments about our article evaluating ocular glaucomatous changes in systemic sclerosis (SSc).

High intraocular pressure ( $>21$  mm Hg) is undoubtedly known to be the main risk factor associated with glaucoma<sup>1</sup>; however, substantial evidence was provided recently to support a key role of vascular abnormalities in the pathogenesis of glaucoma. In particular, patients with normal tension glaucoma, who do not have the main risk factor of developing glaucoma (increased intraocular pressure), may also develop optic neuropathy, and numerous recent studies support the hypothesis that these lesions are associated with vasculopathies.<sup>2-4</sup> These findings led us to investigate the prevalence of glaucomatous changes in SSc, a disease which is strikingly associated with generalised vascular involvement.

Although primary open angle glaucoma is well defined, normal tension glaucoma is more difficult to diagnose. Independently of intraocular pressure, glaucomatous changes are supported by optic disc cupping together with visual field defects.<sup>1</sup> Thus, for the purpose of our comparisons between groups, we had to define cut off values for these two variables. For optic disc cupping, we chose a cut off point based on reported data<sup>5</sup>; we defined mild abnormalities as a c/d  $>0.3$  and severe involvement as a c/d  $>0.7$ . For visual field, we also chose a mean difference  $< -2$  dB according to reported data. Thus, the significant differences between SSc and matched controls for these measures allow us to suggest that patients with SSc have glaucomatous abnormalities as compared with our controls. Although there is no consensual definition of NTG, these results clearly suggest that patients with SSc have glaucomatous propensity. The continuing prospective standardised follow up of our patients and other series will quantify the precise risk factor of SSc for normal tension glaucoma.

#### Y Allanore, A Kahan

Department of Rheumatology A, Paris V University, Cochin Hospital, AP-HP, 75014 Paris, France

#### A Brezin

Department of Ophthalmology, Paris V University, Cochin Hospital, AP-HP, 75014 Paris, France

Correspondence to: Dr Y Allanore, Hôpital Cochin, Service de Rhumatologie A, 27 rue du faubourg Saint-Jacques, 75014 Paris, France; yannick.allanore@cch.ap-hop-paris.fr

## References

- Quigley HA. Open-angle glaucoma. *N Engl J Med* 1993;**328**:1097-106.
- Nicolele MT, Ferrier SN, Morrison CA, Archibald ML, LeVatte TL, Wallace K, *et al*. Effects of cold-induced vasospasm in glaucoma: the role of endothelin-1. *Invest Ophthalmol Vis Sci* 2003;**44**:2565-72.
- Pache M, Dubler B, Flammer J. Peripheral vasospasm and nocturnal blood pressure dipping—two distinct risk factors for glaucomatous damage? *Eur J Ophthalmol* 2003;**13**:260-5.
- Buckley C, Hadoko PW, Henry E, O'Brien C. Systemic vascular endothelial cell dysfunction in normal pressure glaucoma. *Br J Ophthalmol* 2002;**86**:227-32.
- Jonas JB, Gusek GC, Naumann GOH. Optic disc, cup and neuroretinal rim size, configuration and correlations in normal eyes. *Invest Ophthalmol Vis Sci* 1992;**33**:474-5.

## CD68 is not a macrophage-specific antigen

The article of Kunisch *et al* discussing a cross reactivity of allegedly macrophage-specific anti-CD68 antibodies with fibroblasts and activated endothelial cells demonstrates amply that these antibodies should not be used for the identification of macrophages.<sup>1</sup> Yet they have been used for this purpose in nearly all medical disciplines, particularly in vascular diseases. In 1990 we observed that some neointimal cells in experimental transplantation atherosclerosis, human native atherosclerosis, and experimental native atherosclerosis had reacted with both presumptive macrophage-specific antibodies (RAM11, HAM56) and an antibody against muscle actin (HHF35).<sup>2</sup> In 1997, Andreeva *et al* demonstrated that the very same human intimal and neointimal cells were immunopositive, both with anti-macrophage (CD68, HAM56) and anti-muscle actin (asm-1, HHF35) antibodies.<sup>3</sup> On the basis of these findings, these authors formed a hypothesis that the macrophage markers involved in these reactions were not indicative of cell histogenesis but of phagocytosis. Neither our observation<sup>2</sup> nor the demonstration of Andreeva *et al*<sup>3</sup> had any influence on the practice of macrophage identification by the above mentioned antibodies.

Today, I share Kuhn's opinion<sup>4</sup> that the acceptance or rejection of new scientific ideas depends on their relationship to existing paradigms. If they are in agreement with them they are accepted, but if they contradict them they are usually ignored. When the immunohistochemical identification of macrophages was originally proposed there was no existing paradigm in this field and its authors presented their methods against no substantial opposition. My observation that an unreasonably high amount of macrophages had been identified with new monoclonal antibodies in comparison with previously used electron microscopy was disregarded.<sup>5</sup> Rare articles describing the reactivity of the above mentioned anti-macrophage antibodies with other cell phenotypes in other medical disciplines were also neglected.

Kuhn described the scientific process as a conflict, in which less satisfactory paradigms are replaced successively by better ones.<sup>4</sup> There is only one way which guarantees the correctness of individual paradigms: a strict observance of the facts. For example, an immunological injury induces an intimal thickening composed only of "macrophages"

identified by “macrophage-specific” antibodies in a hypercholesterolaemic rabbit. Serial sections show, however, that the cells in question are smooth muscle cells manifesting both macrophage and muscle actin antigens.<sup>2,6</sup> Because macrophages cannot produce muscle actin, the cells must be smooth muscle cells phagocytising lipids, and the paradigm of macrophage-specific antigens should be replaced by the paradigm of phagocytotic antigens.

In the article by Kunisch *et al*,<sup>1</sup> it would be interesting to know whether the extent of the overlap between “macrophage” and fibroblast markers in individual patients correlates with some measures of their rheumatoid arthritis, such as synovium hypertrophy, pannus formation, cartilage erosion, and bone destruction. Also, is there a relationship between anti-CD68 positive synovial fibroblasts and contingent dyslipidaemias in rheumatoid arthritis? In vascular diseases, “macrophage-specific” antibodies react with smooth muscle cell phagocytising lipids.<sup>3</sup> A similar process in which phagocytising synovial fibroblasts would become immunopositive with anti-CD68 antibodies may take place in rheumatoid arthritis.

J T Beranek

4101 South Wappel Drive, Columbia, MO 65203, USA


Correspondence to: Dr J T Beranek, jiriberanek@hotmail.com

arteriosclerosis in rabbits. *J Heart Transplant* 1990;9:18–24.

Authors’ reply

We sincerely thank Dr JT Beranek for his thoughtful letter and his comments on our report. He supports our view that CD68 is not a specific marker for macrophages but rather an antigen indicative of phagocytosis,<sup>1</sup> as also expressed in several studies in atherosclerosis and other areas.<sup>2–8</sup> Our own continuing experiments also support an interrelationship between phagocytosis and the expression of CD68 proteins. After phagocytosis of conventional phosphatidylcholine/phosphatidylglycerol/cholesterol liposomes (24 hours), the human monocytic cell line THP-1 increased the expression of the CD68 epitope recognised by the monoclonal antibody (mAb) EBM11, but not the CD68 epitope recognised by the mAb KP1 (fig 1). In contrast, only marginal effects were seen in human synovial fibroblasts at this time.

To determine whether this finding is based on redistribution,<sup>7</sup> conformational change, or altered glycosylation pattern<sup>8</sup> of the CD68 molecule, or on (trans)differentiation of the



**Figure 1** CD68 expression (mAb EBM11 or KP1, surface and intracellular) of THP-1 cells and synovial fibroblasts after incubation with phosphatidylcholine liposomes for 24 hours (dipalmitoylphosphatidylcholine, dipalmitoylphosphatidylglycerol, cholesterol at a molar ratio of 50:10:40; mean size 495 nm). THP-1 cells were incubated with liposomes in suspension for 24 hours. Synovial fibroblasts were allowed to attach for 24 hours followed by incubation with liposomes for 24 hours. Thereafter, CD68 expression (mAb EBM11 and KP1, surface and intracellular) was determined by flow cytometry (A and B) isotype control – solid line; specific antibody – dashed/solid line; (C) CD68 expression in untreated cells – dashed line; CD68 expression in liposome treated cells – solid line; x axis: fluorescence intensity; y axis: counts).

cells,<sup>6</sup> requires further study. The observation that different types of non-macrophage-like cells express the "macrophage" marker CD68 in several diseases, clearly has the consequence that these "macrophage-like" cells have to be more thoroughly identified using other cell-type specific markers and the appropriate technique and fixation. We also agree with Dr Beranek's point that the revival of morphological or ultrastructural techniques in connection with modern immunohistology/in situ hybridisation is essential in clarifying some of these controversial findings.

As regards the correlations between the extent of overlap between "macrophages" and fibroblast markers in individual patients and their measures of clinical disease or the contingent dyslipidaemias in rheumatoid arthritis, we can only provide a partial answer. When patients with rheumatoid arthritis and osteoarthritis were analysed together by the Spearman rank correlation, the percentage of synovial fibroblasts positive by FACS staining for the anti-CD68 mAbs KP1 or EBM11 showed a significant negative correlation with disease markers such as the number of fulfilled American Rheumatism Association criteria<sup>9</sup> or the number of leucocytes in peripheral blood (maximum  $r_s = -0.715$ ;  $p = 0.006$ ;  $n = 13$ ). Also, the percentages of synovial fibroblasts positive for the KP1 or EBM11 epitopes of CD68 showed a highly significant positive correlation with each other ( $r_s = 0.951$ ;  $p = 0.000$ ;  $n = 13$ ), as well as with other fibroblast markers like Thy-1 (CD90) or prolyl-4-hydroxylase (maximum  $r_s = 0.750$ ;  $p = 0.002$ ;  $n = 14$ ).

Finally, we thoroughly agree with Dr Beranek's thoughtful considerations on the interrelationship between ignoring new scientific evidence and the persistence of incorrect paradigms. His recommendation to return to the strict observance of facts, indeed an incontrovertible basis for scientific conduct, should encourage a discussion on the influence of the human factor<sup>10</sup> in scientific peer review.

**E Kunisch, R Anderson, R W Kinne**  
Experimental Rheumatology Unit, FSU Jena, Germany

**R Fuhrmann, A Roth, R Winter**  
Clinic of Orthopaedics, FSU Jena, Germany

**W Lungershausen**  
Department of Traumatology, FSU Jena, Germany

**U Rauchhaus, S Panzner**  
Novosom AG, Halle, Germany

Correspondence to: Professor R W Kinne,  
raimund.w.kinne@rz.uni-jena.de

## References

- Kunisch E**, Fuhrmann R, Roth A, Winter R, Lungershausen W, Kinne RW. Macrophage specificity of three anti-CD68 monoclonal antibodies (KP1, EBM11, and PGM1) widely used for immunohistochemistry and flow cytometry. *Ann Rheum Dis* 2004;**63**:774-84.
- Beranek JT**, Cavarocchi NC. Smooth muscle cells and macrophages in rabbit cardiac allograft atherosclerosis. *J Heart Transplant* 1990;**9**:732.
- Andreeva ER**, Pugach IM, Orekhov AN. Subendothelial smooth muscle cells of human aorta express macrophage antigen in situ and in vitro. *Atherosclerosis* 1997;**135**:19-27.
- Beranek JT**. Atherosclerosis: a personal view. *Cardiac Chronicle* 1991;**5**:1-6.
- Sasaguri S**, Eishi Y, Tsukada T, Sunamori M, Suzuki A, Numano F, et al. Role of smooth-muscle cells and macrophages in cardiac allograft arteriosclerosis in rabbits. *J Heart Transplant* 1990;**9**:18-24.
- Rong JX**, Shapiro M, Trogan E, Fisher EA. Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading. *Proc Natl Acad Sci USA* 2003;**100**:13531-6.
- Travaglio S**, Falzano L, Fabbri A, Stringaro A, Fais S, Fiorentini C. Epithelial cells and expression of the phagocytotic marker CD68: scavenging of apoptotic bodies following Rho activation. *Toxicol In Vitro* 2002;**16**:405-11.
- Da Silva RP**, Gordon S. Phagocytosis stimulates alternative glycosylation of macrofialin (Mouse CD68), a macrophage-specific endosomal protein. *Biochem J* 1999;**338**:687-94.
- Arnett FC**, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;**31**:315-24.
- Brecht B**. Der verwundete Sokrates. In: Gesammelte Werke. Frankfurt am Main, Germany: Suhrkamp Verlag, 1967.

## FORTHCOMING EVENTS

### Vth European Lupus Meeting

3-5 March 2005; Royal College of Physicians, London, UK

Contact: Julia Kermode, Conference organiser of the British Society of Rheumatology  
Email: Julia@Rheumatology.org.uk

### Thirteenth Intensive Applied Epidemiology Course for Rheumatologists

7-11 March, 2005; Manchester, UK  
No previous experience in epidemiology is required. Residential course limited to 20 places  
Contact: Ms Lisa McClair, ARC Epidemiology Unit, University of Manchester, Oxford Road, Manchester M13 9PT, UK  
Tel: +44 (0) 161 275 5993  
Fax: +44 (0) 161 275 5043  
Email: Lisa.mcclair@man.ac.uk

### International Society for the Study of the Lumbar Spine Instructional Course

27, 28 March 2005; Nairobi, Kenya  
Controversies in diagnosis and treatment of lumbar spine conditions  
Contact: Shirley Fitzgerald, 2075 Bayview Avenue, Room MG323, Toronto, Ontario, Canada M4N 3M5  
Tel: 416 480 4833  
Fax: 416 480 6055  
Email: shirley.fitzgerald@sw.ca

### BSR Annual Meeting 2005

19-22 April 2005; ICC, Birmingham, UK  
Joint meeting with the German Society for Rheumatology  
Contact: BSR, 41 Eagle Street, London WC1R 4TL, UK  
Tel: +44 (0) 20 7242 3313  
Fax: +44 (0) 20 7242 3277

### EULAR 2005

8-11 June 2005, Vienna, Austria  
Contact: EULAR Secretariat  
Tel: +41 1 383 96 90  
Fax: +41 1 383 98 10  
Email: secretariat@eular.org  
Website: <http://www.eular.org/eular2005>

### Future EULAR congresses

21-24 June 2006; EULAR 2006; Amsterdam, The Netherlands  
13-16 June 2007; EULAR 2007; Barcelona, Spain  
11-14 June 2008; EULAR 2008; Paris, France